statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vaccinex Reports 2023 Financial Results and Provides Corporate Update

Expect Topline Data for Phase 1/2a Randomized SIGNAL-AD Study of Pepinemab for Alzheimer's Disease in Q3 2024 Company raised $17.9 million of new financing during Q4 2023 and Q1 2024 ROCHESTER...

Vaccinex, Inc. (NASDAQ:VCNX) Sees Significant Decrease in Short Interest

Vaccinex, Inc. (NASDAQ:VCNX - Get Free Report) saw a significant decline in short interest in March. As of March 15th, there was short interest totalling 8,800 shares, a decline of 40.5% from the...

Vaccinex to raise $1.5M through in a direct offering

Vaccinex to raise $1.5M through in a direct offering...

Vaccinex prices 193,000 shares at $7.77 in registered direct offering

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

ROCHESTER, N.Y., March 27, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) ( Vaccinex or the Company ), a clinical-stage biotechnology company pioneering a differentiated approach to...

12 acciones de salud en movimiento durante la preapertura del 26/02/2024

Acciones al alza
ZyVersa Therapeutics (NASDAQ:ZVSA) avanzaron un 47,31% para establecerse en los 1,18 d lares durante la sesi n del pre-market del lunes.
Vaccinex (NASDAQ:VCNX) crecieron un 43,64...

Vaccinex Announces Multiple New Agreements for Access to ActivMAb  Antigen Virus Technology

Eight new antibody discovery agreements incorporate Vaccinex's powerful ActivMAb Drug Discovery Platform ActivMab platform enables the discovery and development of high value antibodies against...

Vaccinex trading halted, news pending

Vaccinex, Inc. Announces Reverse Stock Split

ROCHESTER, N.Y., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc., (NASDAQ: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease...

12 titres de soins de sant  en mouvement lors de la session apr s-cl ture le 09/02/2024

Gagnants
L'action Vaccinex (NASDAQ:VCNX) a grimp vendredi de 12,48% 0,78 dollars lors de la session after-market.
Le titre Celularity (NASDAQ:CELU) a augment de 7,52% 0,46 dollars.
L'action...

Vaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the development of targeted bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The firm focuses on the development of Pepinemab for the treatment of non-small cell lung cancer, or NSCLC, osteosarcoma, melanoma, and Huntington’s disease. Its product pipeline includes the SEMA4D antibody platform and ActivMAb antibody discovery platform. The company was founded by Maurice Zauderer in April 2001 and is headquartered in Rochester, NY.

Volume	63,572.00
52-Wk High	$64.89
52-Wk Low	$4.43

VCNX Vaccinex Inc

About

Feed

News

Sentiment

Fundamentals